EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Conquering Oxygen Heterogeneity in Hepatocellular Carcinoma With a Dual‐Targeted Nanoplatform Integrating Type I Photodynamic Therapy/Starvation Therapy/Hypoxia‐Activated Chemotherapy

Xiang Wang, Yihan Ma, Hengrui Li, Le Wang, Miao Qin, Rui Lou, Jian Yin, Wenbo Ming, Yong Mao, Jing Hu

Aggregate · 2026-04 · 7 (4)

DOI: 10.1002/agt2.70344 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aggregate, online erschienen am 22.04.2026. Verfasst von Xiang Wang und 9 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) displays severe oxygen heterogeneity, which is regarded as a critical limitation to therapeutic efficacy. Herein, a targeted nanoplatform is engineered to overcome this barrier via a synergistic starvation/chemotherapy/Type I photodynamic therapy (PDT) strategy by co‐encapsulating glucose oxidase (GOx), tirapazamine (TPZ), and photosensitizer (sulfur‐substituted Nile Blue, ENBS) in galactose/biotin dual‐ligand‐modified liposomal nanoparticles (TGoE@BG‐Lipo). ENBS‐enabled Type I PDT provides oxygen‐independent photokilling, whereas GOx‐mediated glucose/oxygen depletion induces starvation and aggravates hypoxia to activate TPZ, together enabling efficient tumor eradication. TGoE@BG‐Lipo exhibits precise targeting with an 84‐fold higher uptake in HCC cells versus normal cells in a coculture model. In vitro, TGoE@BG‐Lipo/L generates O 2 −• through Type I PDT and produces robust reactive oxygen species (ROS) under both normoxic (3.1‐fold vs. untreated control) and hypoxic (2.1‐fold) conditions. This treatment induces both caspase‐3/GSDME‐dependent pyroptosis and immunogenic cell death (ICD) hallmarks upon irradiation. Thus, this synergistic treatment induces potent cell killing characterized by severe mitochondrial dysfunction (45.0% monomers) and achieves a tumor growth inhibition rate of 95.3 ± 1.1% in a hypoxic C5WN1 tumor model. Overall, this study presents a hypoxia‐adaptive nanoplatform for the precise eradication of oxygen‐heterogeneous HCC.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Wang, X., Ma, Y., Li, H., Wang, L., Qin, M., Lou, R., Yin, J., Ming, W., Mao, Y., & Hu, J. (2026). Conquering Oxygen Heterogeneity in Hepatocellular Carcinoma With a Dual‐Targeted Nanoplatform Integrating Type I Photodynamic Therapy/Starvation Therapy/Hypoxia‐Activated Chemotherapy. Aggregate, 7(4). https://doi.org/10.1002/agt2.70344

Vancouver

Wang X, Ma Y, Li H, Wang L, Qin M, Lou R, et al. Conquering Oxygen Heterogeneity in Hepatocellular Carcinoma With a Dual‐Targeted Nanoplatform Integrating Type I Photodynamic Therapy/Starvation Therapy/Hypoxia‐Activated Chemotherapy. Aggregate. 2026;7(4). doi:10.1002/agt2.70344

BibTeX
@article{Wang2026,
  author = {Wang, Xiang and Ma, Yihan and Li, Hengrui and Wang, Le and Qin, Miao and Lou, Rui and Yin, Jian and Ming, Wenbo and Mao, Yong and Hu, Jing},
  title = {Conquering Oxygen Heterogeneity in Hepatocellular Carcinoma With a Dual‐Targeted Nanoplatform Integrating Type I Photodynamic Therapy/Starvation Therapy/Hypoxia‐Activated Chemotherapy},
  journal = {Aggregate},
  year = {2026},
  volume = {7},
  number = {4},
  doi = {10.1002/agt2.70344}
}
Kostenlos starten →